Meeting
2014 Genitourinary Cancers Symposium
Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.
Authors
Matteo Santoni
Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy
Matteo Santoni , Camillo Porta , Giuseppe Procopio , Linda Cerbone , Umberto Basso , Ugo De Giorgi , Mimma Rizzo , Cinzia Ortega , Francesco Massari , Roberto Iacovelli , Giuseppe di Lorenzo , Michele Milella , Roberto Sabbatini , Francesco Atzori , Rocco De Vivo , Rossana Berardi , Daniele Santini , Stefano Cascinu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 421)
DOI
10.1200/jco.2014.32.4_suppl.421
Abstract #
421
Poster Bd #
C7
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.
First Author: Xieqiao Yan
Poster
2021 ASCO Annual Meeting
Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.
First Author: Patrick Joseph O'Shea
Poster
2015 ASCO Annual Meeting
Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents.
First Author: Paolo Grassi
Poster
2022 ASCO Annual Meeting
Racial differences in treatment patterns and outcomes of first-line (1L) therapies for advanced renal cell carcinoma (aRCC) in the real-world (RW) setting.
First Author: Daniel M. Geynisman